Sandell Asset Management’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
Sandell Asset Management's BOLD Position: Q1 2020 in Review
Sandell Asset Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 300,000 shares — an estimated $18M sold.
Sandell Asset Management first reported a position in BOLD in Q4 2019 and held it in 1 quarter. The position peaked at $18M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Sandell Asset Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Sandell Asset Management sold 300,000 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $18M.
- Sandell Asset Management first reported a position in Audentes Therapeutics, Inc in Q4 2019 and held it in 1 quarter.
- Sandell Asset Management's Audentes Therapeutics, Inc position peaked at $18M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Sandell Asset Management's 13F filing for Q1 2020, filed 15 May 2020.